Skip to main content

Table 2 Summary of results*; gut barrier integrity markers, oxidation markers, inflammatory markers

From: Effects of zeolite supplementation on parameters of intestinal barrier integrity, inflammation, redoxbiology and performance in aerobically trained subjects

Variable

Ptreat

Ptime

Zeolite

Placebo

Zeolite

Placebo

Reference range

0 week

0 week

12 weeks

12 weeks

zonulin

0.006

>0.1

61.2 ± 11.0

56.1 ± 13.2

43.8 ± 14.3

59.6 ± 12.3

<55

ng . mL-1

α1-antitrypsin

>0.1

>0.1

27.6 ± 14.8

32.8 ± 15.6

30.2 ± 18.1

35.8 ± 17.7

<37.5

mg . dL-1

CP

>0.1

<0.001

218 ± 102

206 ± 98

508 ± 108

486 ± 87

80–200

pmol . mg-1

iPF2α-III

>0.1

>0.1

216 ± 55

200 ± 55

199 ± 73

181 ± 43

50–400

pg . mL-1

GPx3

>0.1

<0.001

131 ± 69

107 ± 58

182 ± 64

193 ± 59

33–98

IU . L-1

DNA SB

>0.1

>0.1

0.36 ± 0.25

0.35 ± 0.24

0.49 ± 0.33

0.48 ± 0.29

0–70

AU

TNF-α

>0.1

0.024

26.1 ± 8.7

24.3 ± 12.3

31.8 ± 11.5

28.7 ± 11.8

0–69

pg . mL-1

IL-6

>0.1

>0.1

26.6 ± 2.0

27.1 ± 1.7

27.7 ± 3.2

26.9 ± 2.7

<100

pg . mL-1

IL-8

>0.1

>0.1

38.1 ± 10.8

41.9 ± 12.0

39.7 ± 11.5

39.8 ± 9.7

0–62

pg . mL-1

IL-10

0.087

>0.1

40.1 ± 19.2

42.1 ± 16.0

54.5 ± 27.8

37.9 ± 22.2

none

pg . mL-1

IL-22

>0.1

>0.1

42.9 ± 4.2

41.4 ± 3.3

40.5 ± 3.3

40.1 ± 4.4

none

pg . mL-1

  1. *Values are means ± SD; P < 0.05, ANOVA; n = 27 (Zeolite), n = 25 (Placebo); α1-antitrypsin alpha1-antitrypsin, CP carbonyl groups bounded on protein, iPF2α-III isoprostanes F2α-III, GPx3 plasma glutathione peroxidase, DNA SB DNA strand-breaks, TNF-α tumor necrose factor alpha, IL interleukin, treat treatment